U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
Notified -
Globe Newswire21-02-2026, 02:43
Sartorius and va-Q-tec announce a long-term partnership for the joint development of innovative transport systems for the biopharmaceutical industry 27-04-2023, 14:00